How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,216 results for

adhd Methylphenidate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD)

programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders. Final Appraisal Recommendation (FAR) Download AWMSG Secretariat Appraisal Report (ASAR) Download Clinical Expert (CE) Summary Download | (...) Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD) All Wales Medicines Strategy Group (AWMSG) - lisdexamfetamine dimesylate (Elvanse) | | Appraisal information Search and reports lisdexamfetamine dimesylate (Elvanse®) Reference No. 188 Publication date: 03/12/2013 Last review date: 01/12/2016 Appraisal information lisdexamfetamine dimesylate (Elvanse®) 30 mg capsule lisdexamfetamine dimesylate (Elvanse®) 50 mg capsule lisdexamfetamine dimesylate (Elvanse®

2013 All Wales Medicines Strategy Group

22. The effect of adding ferrous sulfate to methylphenidate on attention-deficit/hyperactivity disorder in children. Full Text available with Trip Pro

The effect of adding ferrous sulfate to methylphenidate on attention-deficit/hyperactivity disorder in children. Attention deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in children with several complications. This study was conducted to investigate the effect of adding ferrous sulfate to methylphenidate in decreasing ADHD symptoms. This study was a double-blind, randomized clinical trial. In this study, 42 nonanemic children with ADHD and serum ferritin (...) , and repeated measures ANOVA in SPSS 16. The scores on CSI-4 decreased significantly at month 2 in both groups (P < 0.001). The scores on attention deficit and hyperactivity subscales of the CSI-4 were significantly lower in the case group than the control group (P < 0.05). The total score on CSI-4 decreased more markedly in the case group (P < 0.04). Use of ferrous sulfate plus methylphenidate can be effective in reducing ADHD symptoms in nonanemic children with low serum ferritin.

2019 Journal of advanced pharmaceutical technology & research Controlled trial quality: uncertain

23. Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Full Text available with Trip Pro

Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Attention deficit-hyperactivity disorder (ADHD) is one of the most common chronic behavioral disorders in school-aged children.This study aimed to evaluate the effect of omega-3 supplementation as an alternative therapy for ADHD, which can be caused by vitamin and mineral deficiencies.This was a double-blinded clinical trial study. Sixty-six children with ADHD (aged 6 (...) -12 years) referred to our child and adolescent psychiatric educational and therapeutic clinic were selected based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria. Instruments including the Parent ADHD Rating Scale were used to assess ADHD at 0, 2, 4, and 8 weeks during the study.The results showed no statistically significant difference between the methylphenidate with omega-3 group and methylphenidate with placebo group based on the Parents ADHD

2019 Korean journal of pediatrics Controlled trial quality: uncertain

24. White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. Full Text available with Trip Pro

White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. BackgroundMethylphenidate (MPH) is highly effective in treating attention-deficit/hyperactivity disorder (ADHD). However, not much is known about its effect on the development of human brain white matter (WM).PurposeTo determine whether MPH modulates WM microstructure in an age-dependent fashion in a randomized double-blind placebo-controlled (...) size, 5.25) in MPH-treated boys. Similar changes were not present in boys receiving a placebo, nor in adult men.ConclusionFour months of treatment with methylphenidate affects specific tracts in brain white matter in boys with attention-deficit/hyperactivity disorder. These effects seem to be age dependent, because they were not observed in adults treated with methylphenidate.© RSNA, 2019Online supplemental material is available for this article.

2019 Radiology Controlled trial quality: predicted high

25. Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder. (Abstract)

Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder. This study aimed to compare the effectiveness of parental training (PT), methylphenidate treatment (MPH), and the combination of PT and MPH treatment (PT/MPH) on school achievements in children with attention-deficit hyperactivity disorder (ADHD). Twenty eight ADHD patients (age: 10.1±1.11 years) were (...) ). Methylphenidate alone is superior to either parental training or parental training/methylphenidate in improving academics and conduct at school.

2019 International clinical psychopharmacology Controlled trial quality: uncertain

26. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings. Full Text available with Trip Pro

A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings. Objectives: HLD200, a once-daily, evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH), was designed to provide therapeutic effect beginning upon awakening and lasting into the evening. This pivotal, randomized (...) , double-blind, multicenter, placebo-controlled, phase 3 trial assessed improvements in functional impairment across the day using multiple validated measures tailored for different settings and time of day in children (6-12 years) with attention-deficit/hyperactivity disorder (ADHD). Methods: Following a 6-week, open-label titration of DR/ER-MPH to an optimal dose (20, 40, 60, 80, or 100 mg/day) and dosing time (8:00 PM ±1.5 hours), participants were randomized to treatment-optimized DR/ER-MPH

2019 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: predicted high

27. The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. (Abstract)

The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. The current study aimed to explore the possible effect of stimulants on oxytocin (OT), a neuropeptide which regulates social behavior, as a mediator of the pro-social effect of methylphenidate (MPH) in children with attention deficit hyperactivity disorder (ADHD) compared to healthy controls (HCs). Utilizing a double-blind placebo-controlled design, we compared (...) with an increase in OT levels after the parent-child interaction. We conclude that OT might play a role as a mediator of social deficits in children with ADHD and that the reactivity of the OT system to social interaction in children with ADHD might be impaired. Stimulants may improve ToM and social functions in children with ADHD via its impact on the OT system. PRS: OT and Social Cognition in Children with ADHD: Impact of MPH.

2019 Neuropsychopharmacology

28. Correction: The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. Full Text available with Trip Pro

Correction: The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

2019 Neuropsychopharmacology

29. Does L-Methylfolate Supplement Methylphenidate Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder?: Evidence of Lack of Benefit From a Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Full Text available with Trip Pro

Does L-Methylfolate Supplement Methylphenidate Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder?: Evidence of Lack of Benefit From a Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Interventions for attention-deficit/hyperactivity disorder (ADHD) may be inadequate for some patients. There is evidence that supplementation with L-methylfolate augments antidepressant agent effects and thus might also augment ADHD treatment effects by a common catecholaminergic (...) mechanism.Forty-four adults with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of ADHD participated in a randomized, double-blind, placebo-controlled, 12-week trial of 15 mg of L-methylfolate in combination with osmotic-release oral system methylphenidate. Osmotic-release oral system methylphenidate was dose optimized over the first 6 weeks. We evaluated the effects on ADHD symptoms, self-report on the Behavior Rating Inventory of Executive Function of executive function

2019 Journal of Clinical Psychopharmacology Controlled trial quality: uncertain

30. A Quantitative Comparison Approach for Methylphenidate Drug Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. (Abstract)

A Quantitative Comparison Approach for Methylphenidate Drug Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. Different methylphenidate (MPH) formulations, immediate release (IR) or extended release (ER), have been developed to treat Attention-Deficit/Hyperactivity Disorder (ADHD). A better use of these formulations, with a proper choice of their timing, dosage, and combination, can help to attain optimal therapeutic effect while maintaining a good quality of life. In this study (...) clinical situations, the three-methods strategy is able to distinguish the regimens proposed for each. A combined regimen of IR and ER taken at the same time performs better than a single ER dose.The proposed statistical strategy is able to differentiate ADHD regimens in various clinically relevant situations, and adapt the use of MPH drugs to a patient's daily routine. Since it does not compare fixed doses and formulations but rather any MPH regimen, our approach generalizes the current context

2019 Journal of Child and Adolescent Psychopharmacology

31. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. (Abstract)

Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric disorders of childhood and adolescence. About 30% of patients do not respond to stimulants or cannot tolerate their side effects. Thus, alternative medication, like herbal medicine, should be considered. The aim of this trial is to compare the safety (...) ). Symptoms were assessed using the Teacher and Parent Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) at baseline and weeks 3 and 6.Fifty patients completed the trial. General linear model repeated measures showed no significant difference between the two groups on Parent and Teacher Rating Scale scores (F = 0.749, df = 1.317, p = 0.425, and F = 0.249, df = 1.410, p = 0.701, respectively). Changes in Teacher and Parent ADHD Rating Scale scores from baseline to the study end were

2019 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

32. Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness

patients with ADHD. Tags amphetamine, attention deficit disorder with hyperactivity, delayed-action preparations, dexamfetamine, dexedrine, dexmethylphenidate, dextroamphetamine, focalin, learning disorders, methylphenidate, ritalin, learning disorder, AD/HD, ADD, Adderall, Attention deficit, Concerta, Long acting, Slow acting, atomoxetine, controlled delivery, controlled release, delayed release, extended release, immediate release, lisdexamfetamine dimesylate, short acting, sustained release, vyvanse (...) Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness Published on: February 23, 2016

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

33. High-dose Stimulants for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness, Safety and Guidelines

in adolescents with ADHD was identified; high doses of study medication were more effective than placebo at addressing symptoms, but had uncertain effects on quality of life measures. Three non-randomized studies regarding adverse events for adolescents and adults using high doses of methylphenidate were identified; these doses were generally well tolerated by patients. Tags amphetamine, amphetamines, attention deficit disorder with hyperactivity, central nervous system stimulants, dexamfetamine, dexedrine (...) : A Review of the Clinical Effectiveness, Safety, and Guidelines Published on: March 3, 2016 Project Number: RC0754-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the effectiveness and safety of high dose stimulants in children and adolescents (six to 18 years) with attention-deficit/hyperactivity disorder (ADHD)? What is the comparative effectiveness and safety of high dose stimulants in adults (> 18 years) with ADHD? What

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

34. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. (Abstract)

Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. The aim of this study was to compare children and adolescents with attention-deficit/hyperactivity disorder (ADHD) to healthy children and adolescents in terms of state and trait empathy and emotion expression recognition skills. The goal was also to determine whether (...) there are changes in emotion recognition and empathy measures in children with ADHD after methylphenidate (MPH) treatment.The research sample consisted of outpatient drug-naive children and adolescents between the age of 8 and 14 years (n = 65) with ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. criteria, and healthy children and adolescents of the same age (n = 61). Scores of the oppositional problems (OPs) and conduct problems (CPs) were obtained to evaluate their impact

2017 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

35. A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an exploratory analysis of predictors and moderators of treatment outcome. Full Text available with Trip Pro

A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an exploratory analysis of predictors and moderators of treatment outcome. We examined predictors and moderators of treatment outcome in mothers and children diagnosed with ADHD in a large multicentre RCT.In total, 144 mother-child dyads with ADHD were randomly assigned to either a maternal ADHD treatment (group psychotherapy and open methylphenidate (...) in the family at baseline predicted more externalizing symptoms in the child after PCT, independent of maternal treatment. When mothers had a comorbid depression, TG children showed more externalizing symptoms after PCT than CG children of depressive mothers. No differences between the treatment arms were seen in the mothers without comorbid depression.Severely impaired mothers with ADHD and depressive disorder are likely to need additional disorder-specific treatment for their comorbid psychiatric

2019 Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie Controlled trial quality: uncertain

36. The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. (Abstract)

The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. Impaired decision making in patients with borderline personality disorder (BPD) has been reported in several studies. Although methylphenidate (MPH) is known to ameliorate impaired decision making in patients with attention-deficit/hyperactivity disorder (ADHD), it has not yet been examined in patients with BPD. We therefore assessed the efficacy (...) of a single dose of MPH on cognitive functions and decision making in patients with BPD. Twenty-two patients diagnosed with BPD participated in the study. The study was a randomized, double-blind placebo-controlled, random block order cross-over trial. Patients participated in two sessions and performed the Test of Variables of Attention, a digit-span test, and the computerized Iowa Gambling Task, after they had been administered either the MPH or a placebo. ADHD symptoms were assessed using the Adult

2018 International clinical psychopharmacology Controlled trial quality: uncertain

37. Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study. (Abstract)

Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study. Disruptive mood dysregulation disorder (DMDD) is characterized by nonepisodic irritability and has a high rate of comorbidity with attention-deficit/hyperactivity disorder (ADHD). This is the first study to explore the effects of aripiprazole combined with methylphenidate on clinical symptoms and cognitive functions (...) group consisting of patients with ADHD (the ADHD Group, n = 27) was recruited to investigate the differences in clinical and neuropsychological profiles between the two groups at baseline.The DMDD-ADHD Group showed worse irritability, disruptive behaviors, anxious/depressed symptoms, and social problems relative to the ADHD Group at baseline assessments. The combination treatment significantly improved irritability, externalizing symptoms, depression, anxiety, attention, social problems

2018 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

38. Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder. Full Text available with Trip Pro

Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder. The purpose of this open-label study was to examine the effects of long-acting methylphenidate (MPH) treatment on irritability and related emotional symptoms associated with disruptive mood dysregulation disorder (DMDD) in youth with comorbid attention-deficit/hyperactivity disorder (ADHD).The sample included 22 (...) , and negative affect (NA). Multiple regression was used to examine the impact baseline hyperactivity, age, gender, race, socioeconomic status, or comorbid diagnosis had on treatment outcomes.Significant improvements (medium to large effect sizes) in child-rated irritability as well as parent and child ratings of emotional lability, NA, and anger were found. As anticipated, ADHD symptoms also improved. While a majority of the sample saw improvement in child-rated irritability (71%), symptoms worsened a small

2018 Journal of Child and Adolescent Psychopharmacology

39. Social adjustment and family function after drug switch from IR-methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder Full Text available with Trip Pro

Social adjustment and family function after drug switch from IR-methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder This prospective, single-arm, open-label, 8-week, multicenter study investigated the effectiveness of switching from immediate-release methylphenidate (IR-MPH) to osmotic controlled-release methylphenidate (OROS-MPH) in patients with attention-deficit/hyperactivity disorder (ADHD).Overall, 296 patients with ADHD (mean age: 9.5 years (...) to OROS-MPH improved patients' behavioral ADHD symptoms and social adjustment, and mental health of patients' mothers. This was most evident in patients who previously exhibited poor IR-MPH adherence.

2018 Neuropsychiatric disease and treatment

40. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate

hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. Lisdexamfetamine dimesylate is a pharmacologically inactive pro-drug that is converted into the central nervous system stimulant, dexamfetamine. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (NICE guideline CG72, published in 2008) recommends that drug treatment for children and young people (...) with ADHD should always form part of a comprehensive treatment plan that includes psychological, behavioural and educational advice/interventions. It also recommends Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 20that when drug treatment of ADHD is considered appropriate, methylphenidate, atomoxetine

2013 National Institute for Health and Clinical Excellence - Advice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>